Shire/Baxalta Merger's Benefits Doubted By Wall Street
This article was originally published in The Pink Sheet Daily
Although Shire struggled toward this merger for five months and says it will position Shire as the top rare disease company in the world, analysts question the long-term viability of Baxalta's hemophilia franchise and whether the total benefits warrant the price being paid.
You may also be interested in...
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.